426 related articles for article (PubMed ID: 36278465)
1. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins.
Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J
Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465
[TBL] [Abstract][Full Text] [Related]
2. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
[TBL] [Abstract][Full Text] [Related]
3. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
Skariyachan S; Gopal D; Chakrabarti S; Kempanna P; Uttarkar A; Muddebihalkar AG; Niranjan V
Comput Biol Med; 2020 Nov; 126():104054. PubMed ID: 33074111
[TBL] [Abstract][Full Text] [Related]
4. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
5. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
Deshpande RR; Tiwari AP; Nyayanit N; Modak M
Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
[TBL] [Abstract][Full Text] [Related]
6. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
7. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
8. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An
Behera SK; Mahapatra N; Tripathy CS; Pati S
Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):132-143. PubMed ID: 33818470
[TBL] [Abstract][Full Text] [Related]
9. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
10. Multi-Targeted Molecular Docking and Drug-Likeness Evaluation of some Nitrogen Heterocyclic Compounds Targeting Proteins Involved in the Development of COVID-19.
Hui LY; Mun CS; Sing LC; Rajak H; Karunakaran R; Ravichandran V
Med Chem; 2023; 19(3):297-309. PubMed ID: 35713125
[TBL] [Abstract][Full Text] [Related]
11. COVID-19: Potential Repurposing Drugs.
Leowattana W
Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
[TBL] [Abstract][Full Text] [Related]
12. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
J Biosci; 2020; 45(1):. PubMed ID: 33184246
[TBL] [Abstract][Full Text] [Related]
13. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
15. Marine Brominated Tyrosine Alkaloids as Promising Inhibitors of SARS-CoV-2.
El-Demerdash A; Hassan A; Abd El-Aziz TM; Stockand JD; Arafa RK
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684755
[TBL] [Abstract][Full Text] [Related]
16. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.
Khursheed A; Jain V; Rasool A; Rather MA; Malik NA; Shalla AH
Microb Pathog; 2021 Aug; 157():104933. PubMed ID: 33984466
[TBL] [Abstract][Full Text] [Related]
17. Impact of repurposed drugs on the symptomatic COVID-19 patients.
Hussain I; Hussain A; Alajmi MF; Rehman MT; Amir S
J Infect Public Health; 2021 Jan; 14(1):24-38. PubMed ID: 33341481
[TBL] [Abstract][Full Text] [Related]
18. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
19. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
More SA; Patil AS; Sakle NS; Mokale SN
Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
[TBL] [Abstract][Full Text] [Related]
20. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]